Sutent fails Phase III liver cancer trial versus Nexavar
This article was originally published in Scrip
Executive Summary
Pfizer has discontinued a Phase III trial of Sutent (sunitinib) in advanced hepatocellular carcinoma (liver cancer), after it failed to show that it was either superior or non-inferior to its rival, Bayer/Onyx's Nexavar (sorafenib).